There is no single best medicine for ulcerative colitis. The right choice depends on how severe your disease is, where inflammation sits in your colon, and whether you’ve tried other treatments before. Mild-to-moderate UC typically starts with a class of anti-inflammatory drugs called 5-ASAs, while moderate-to-severe disease calls for stronger options like biologics, JAK inhibitors, or newer oral therapies. Here’s how each category works and what the evidence says about them.
5-ASAs: The First-Line Treatment for Mild UC
For most people diagnosed with mild-to-moderate ulcerative colitis, treatment begins with mesalamine (a 5-ASA drug). It works by reducing inflammation directly in the lining of the colon, and it comes in oral tablets, granules, suppositories, enemas, and foams. Oral mesalamine reliably induces remission and clinical improvement compared to placebo in mild-to-moderate disease, and different brand formulations perform similarly to one another in head-to-head comparisons.
If your inflammation is limited to the rectum or the lower left side of the colon, topical mesalamine (suppositories or enemas) tends to work better than oral pills alone. Combining oral and rectal mesalamine is a common strategy for people who don’t fully respond to one form by itself. Sulfasalazine, the original 5-ASA, is still used and is particularly affordable, though it carries more side effects like nausea and headache than newer mesalamine formulations. Once remission is achieved, most people stay on a maintenance dose of mesalamine long term to prevent flares.
Steroids for Flares, Not Long-Term Use
Corticosteroids are not a long-term solution, but they play a critical role in putting out the fire during a flare. Standard oral prednisone, typically started at 40 mg daily and tapered by 5 mg each week over roughly nine weeks, is the go-to for moderate-to-severe flares. For mild-to-moderate disease, budesonide MMX is a lower-risk alternative. It’s designed to release medication directly in the colon and causes fewer body-wide side effects like weight gain, mood changes, and bone thinning. The recommended course is 9 mg daily for up to eight weeks.
A rectal foam version of budesonide also exists for inflammation in the lower colon, used twice daily for two weeks and then once daily for four weeks. The key point with any steroid: it buys time for a maintenance therapy to kick in. If you find yourself needing steroids more than once or twice a year, that’s a strong signal your maintenance medication needs to change.
Biologics for Moderate-to-Severe Disease
When 5-ASAs aren’t enough, biologics are the next major step. These are proteins, given by infusion or injection, that block specific parts of the immune system driving inflammation. Several classes exist, and the American Gastroenterological Association ranks them by efficacy tiers for people who haven’t tried advanced therapies before.
Anti-TNF Drugs
Infliximab was the first biologic approved for UC and remains one of the highest-efficacy options. It’s given by IV infusion, typically every eight weeks after an initial loading phase. Combining infliximab with an immunomodulator (a pill that dampens the broader immune response) improves results compared to using either drug alone. Adalimumab, a self-injected alternative, is more convenient but consistently ranks as a lower-efficacy option. In the landmark VARSITY trial, vedolizumab outperformed adalimumab: 31.3% of patients on vedolizumab achieved clinical remission at one year compared to 22.5% on adalimumab, with mucosal healing rates of 39.7% versus 27.7%.
Gut-Selective and Immune-Targeting Biologics
Vedolizumab works differently from anti-TNF drugs. Instead of blocking inflammation throughout the body, it specifically prevents immune cells from migrating into the gut. This targeted approach gives it a favorable safety profile. The rate of serious infections with vedolizumab sits around 4.2 per 100 patients, compared to 6.7 per 100 patients for anti-TNF drugs as a class.
Ustekinumab blocks a different pair of immune signaling molecules and is effective both as a first advanced therapy and after anti-TNF failure. In a real-world study of 293 patients who had already failed an anti-TNF drug, ustekinumab and vedolizumab produced similar rates of clinical remission at 16 weeks (around 38 to 40%). But ustekinumab showed significantly better endoscopic healing (17.5% vs. 5.3%) and deeper tissue-level healing (11.1% vs. 2.1%). Ustekinumab also carries a low rate of serious infections, roughly 0.83 per 100 person-years compared to 2.49 per 100 person-years for infliximab.
Two newer biologics, risankizumab and guselkumab, target related immune pathways and are categorized among the higher-efficacy options by current guidelines. They expand the choices available, particularly for people cycling through treatments.
JAK Inhibitors: Fast-Acting Oral Options
JAK inhibitors are pills that interrupt immune signaling inside cells, and they work faster than most biologics because they don’t need weeks to build up in your system. Three are available for UC: upadacitinib, tofacitinib, and filgotinib.
Upadacitinib is the strongest performer in this class. In real-world data, 86.4% of patients on upadacitinib achieved a significant reduction in gut inflammation markers, compared to 62.5% for tofacitinib and 50% for filgotinib. Current guidelines place upadacitinib and tofacitinib in the higher-efficacy tier, while filgotinib falls into the intermediate tier. Importantly, upadacitinib and tofacitinib are among the preferred options even after a previous biologic has failed, a situation where many other therapies lose effectiveness.
The tradeoff is safety. JAK inhibitors carry risks that other UC therapies don’t, including elevated cholesterol, blood clots, and reactivation of the shingles virus. These risks are most relevant for people over 65 or those with existing heart disease or clotting disorders. Your doctor will likely recommend a shingles vaccine before starting and will monitor bloodwork regularly.
S1P Receptor Modulators: A Newer Oral Class
Ozanimod and etrasimod represent the newest category of UC treatments. They work by trapping certain immune cells in your lymph nodes, preventing them from reaching the colon and causing inflammation. Both are taken as once-daily pills.
Etrasimod proved effective in two large phase 3 trials (the ELEVATE studies), achieving its primary goal of clinical remission for both short-term induction and long-term maintenance. Both drugs are classified as higher-efficacy options for people new to advanced therapy. However, if you’ve already failed an anti-TNF biologic, their effectiveness drops, and guidelines reclassify them as lower-efficacy choices in that scenario. They require heart monitoring before the first dose because they can temporarily slow heart rate.
How Doctors Choose Between Options
The decision isn’t just about which drug has the highest remission rate on paper. Several practical factors shape the choice. If you’ve never taken a biologic or advanced therapy, you have the widest range of higher-efficacy options: infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, risankizumab, and guselkumab all sit in the top tier. If you prefer pills over injections or infusions, upadacitinib, ozanimod, and etrasimod are attractive oral alternatives to IV or injectable biologics.
If a previous anti-TNF drug stopped working for you, the landscape shifts. Upadacitinib, tofacitinib, and ustekinumab become the top-tier choices, while vedolizumab and the S1P modulators become less reliable. This is why treatment history matters as much as disease severity when picking a medication.
Combination therapy also plays a role. Anti-TNF biologics (infliximab, adalimumab, golimumab) perform better when paired with an immunomodulator pill, so your doctor may recommend both. Other biologics and small molecules are typically used alone.
Biosimilars Can Lower Cost Without Losing Efficacy
Several biosimilars are now available for infliximab and adalimumab. These are near-identical copies of the original biologic, approved through rigorous testing that confirms they match the original drug’s effectiveness and safety. In clinical trials, biosimilar infliximab produced response rates virtually identical to the branded version, with no significant differences in side effects. If cost or insurance coverage is a factor, biosimilars are a legitimate way to access high-efficacy treatment at a lower price.
Tracking Whether Your Treatment Is Working
Symptom improvement matters, but the deeper goal of UC treatment is mucosal healing, meaning the inflammation visible during a colonoscopy has resolved. A stool test called fecal calprotectin (FC) lets you and your doctor monitor inflammation without repeated colonoscopies. An FC level between 75 and 100 micrograms per gram is the target range associated with true tissue-level healing. Older guidelines used thresholds of 150 to 250, but recent evidence suggests those cutoffs aren’t strict enough to confirm deep remission. If your FC stays consistently below 100, that’s a strong sign your current medication is doing its job.